Evaluates safety and effectiveness of Teclistamab in therapy-refractory patients with autoimmune neuropathies, suggesting potential for improved outcomes.
Evaluation whether treatment with the bispecific T-cell engager Teclistamab is effective and safe in therapy-refractory patients with IgM paraproteinemic neuropathies.
No takes yet. Share an insight, caveat, or question.
Wickel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: